Reckitt Benckiser Says It’s Among Bidders For Merck Consumer Arm

Reckitt Benckiser Group Plc (RB/), the maker of Durex condoms, said it’s among bidders for Merck & Co.’s consumer unit, a deal that would add Claritin allergy medicine and Coppertone sunblock to its growing stable of over-the-counter remedies.

“We understand that we are part of a competitive process,” the Slough, England-based company said today in a statement. “There is absolutely no certainty as to the outcome or timing of this process.”

Reckitt is among bidders including Procter & Gamble Co. and Bayer AG for the business, people familiar with the matter have said. Representatives for Bayer, P&G and Merck declined to comment earlier on the matter.

Acquiring the Merck unit would make Reckitt Benckiser the third-biggest global seller of consumer-health products, up from number nine currently. Since taking over from Bart Becht in 2011, Chief Executive Officer Rakesh Kapoor has grown Reckitt Benckiser’s consumer-health division through acquisitions to offset slowing growth at its household-cleaning unit.

The health segment accounts for about 30 percent of the company’s 10 billion pounds ($16.8 billion) in revenue, up from 5 percent in 2005, and adding the Merck brands would increase that to about 37 percent. Reckitt Benckiser, which sells a drug to help people quit heroin use, would also be paying for earnings growth after putting its pharmaceuticals business under review.

The Merck unit reported $1.9 billion in sales last year, down 3 percent from 2012 after the termination of some distribution agreements in China. Merck decided to put that business and its animal-health unit under review last year in order to allocate more capital to new drugs like its immune system-based cancer medicine, CEO Ken Frazier has said.

To contact the reporter on this story: Matthew Boyle in London at mboyle20@bloomberg.net

To contact the editors responsible for this story: Celeste Perri at cperri@bloomberg.net Robert Valpuesta

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.